# KARMA_pQTL_MR

Code to support  
Evaluation of Circulating Plasma Proteins in Breast Cancer: A Mendelian Randomisation Analysis  
Anders Mälarstig1,2, Felix Grassmann1,3, Leo Dahl4, Marios Dimitriou1,2, Dianna McLeod1, Marike Gabrielson1, Karl Smith-Byrne5, Cecilia E. Thomas4, Tzu-Hsuan Huang6, Simon KG Forsberg7, Per Eriksson7, Mikael Ulfstedt7, Mattias Johansson8, Aleksandr V. Sokolov9, Helgi B. Schiöth9, Per Hall1, 10, Jochen M. Schwenk4, Kamila Czene1, Åsa K. Hedman1,2

1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
2. Pfizer Worldwide Research Development and Medical, Stockholm, Sweden
3. Institute of Clinical Research and Systems Medicine, Health and Medical University, Potsdam, Germany
4. Science for Life Laboratory, Department of Protein Science, KTH Royal Institute of Technology, Solna, Sweden
5. Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford
6. Cancer Immunology Discovery, Pfizer Inc., San Diego, California
7. Olink Proteomics AB, Uppsala, Sweden
8. Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
9. Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden.
10. Department of Oncology, Södersjukhuset, Stockholm, Sweden

Corresponding author:  
Anders Malarstig, Ph.D.,  
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet  
Nobels väg 12A  
171 65 Stockholm, Sweden  
Phone: +46 (0) 8-55052514 E-mails: anders.malarstig@ki.se, anders.malarstig@pfizer.com